logo IAF

INDIAN ACHIEVERS' FORUM

Registered under the Society Act, 1860
Govt. of India Recognized 80G, 12A compliant
24 years of Excellence

G20 summit logo
iaf awards logo
Azadi-Ka-Amrit-Mahotsav-Logo
Prof. Dr Kannan Vishwanatth

Achiever's Success Story

The Journey from Corporate World and to Philanthropic & Academic ventures

Visionary entrepreneur Dr. Kannan Vishwanatth based out of Riga, Latvia is the Founder & Managing Director of our Hong Kong-based pharmaceutical company Rupus Global Limited. He holds a doctorate in Business Management (Ph.D.). Dr. Kannan Vishwanatth is a global opinion maker on contemporary issues & a much sought-after speaker in various international forums. As a Research Scholar, Dr. Kannan has published many research papers & is associated with many top-notch International Institutions as Editorial Reviewer. Dr. Kannan Vishwanatth is a global Citizen & a strong believer in Corporate Social Responsibilities.

Over the years, Dr. Kannan has slowly transitioned away from Corporate World and into philanthropic & academic ventures. Dr. Kannan Vishwanatth is a top academic researcher at the Garwood Innovation Fellow at Garwood Centre of Open Innovation, Haas School of Business Berkeley University of California & Senior Research Scholar at the Latvian Academy of Sciences in Riga. Dr. Vishwanatth further pursued higher studies at the University of Azteca European Programs. Having mastered Chemical Engineering, Vishwanatth started his entrepreneurial journey a decade ago and formed a successful mid-sized pharmaceutical company with a major thrust on API (Active Pharmaceutical Ingredient). Dr. Kannan Vishwanatth along with Prof. Solomon Darwin, Director, Garwood Center for Corporate Innovation, Executive Director, Center for Growth Markets, Institute for Business Innovation & Dr. Satya Brahma, Chairman & Editor-In-Chief, Network 7 Media Group, Founder & Chairman, Pharma Leaders & India Leadership Conclave co-authored a research book on Smart Villages – A Game-Changing Innovations in Social Engineering in the year 2022.

(Prof) Dr Kannan Vishwanatth joins a prestigious academic group of individuals who have been similarly honored over the years at the University of California, Berkeley. (Prof) Dr Kannan Vishwanatth has been a Doctoral Fellow at the Institute of Professional Financial Managers, United Kingdom. (Prof) Dr Kannan Vishwanatth is best known for co-authoring & publishing notable milestones in the patents of transdermal formulations and Anti-Cancer API’s.

(Prof) Dr Kannan Vishwanatth has also been awarded the prestigious The Albert Schweitzer Medal in Science 2017, The Malcolm Adishesish Award for Development Studies 2020, The Professional Academic Award 2019, The American College Dubai UAE & GSIR Foundation, Outstanding Entrepreneur Award 2011, Asia Pacific Entrepreneurship Award (APEA). (Prof) Dr Kannan Vishwanatth did Bachelor of Petroleum Engineering in the year 1992-1996 from Maharashtra Institute of Technology in Pune in India, followed by Asia-E-University and Indian Institute of Research and Management India Master’s in Business Administration in the year 2008-2009. (Prof) Dr Kannan Vishwanatth further pursued higher studies from the University of Azteca European Programs and Indian Institute of Research and Management India Doctor of Philosophy in Business Management (2009-2012).

Prof Dr Kannan Vishwanatth is a world leader in strategy and innovation, has presented many research papers in the international conferences, delivered keynote addresses in London, America, Paris, Germany etc.

Rupus Global Limited is a market leader in the Antimalarial API segment and is the world’s third-largest contract manufacturer of Quinine salts. Rupus Global Limited product portfolio consists of the second generation, Quinine-based antimalarial APIs, third-generation Artemisinin-based antimalarial APIs; Niche APIs, and FDFs complimented by APIs in HIV, Diabetes, Ace Inhibitor, and CNS.

Rupus Global Limited has a distributor network of over 250 distributors in India and has entered into a marketing and distribution agreement with Rx Pharma (India) to distribute the company’s products domestically. It also exports its products to more than 60 emerging countries in Africa, Central and South America, and Asia. The Company’s API business has grown rapidly since its commencement in FY2018 and currently contributes over 60 per cent of total revenues while its formulations business contributes over 40 per cent of total revenues.

More Stories

Mr. Raj Sinha

Achiever’s Success Story “Mr.Raj Sinha, Managing Director, MEDVENT” Winston S. Churchill has rightly said, “Success

Read More »
Scroll to Top
Make payment in favour of:  
BRANDWORKS MEDIA PRIVATE LIMITED
 
Account No.: 

9810066763

Bank Name: Kotak Mahindra Bank
Branch: Mayur Vihar-I, Delhi -110091

IFSC CODE :  KKBK0000203
MICR No.: 110485046

===================== 

If you are choosing this payment option, then please select and copy the above text before closing this pop-up.